Merck Stock News

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

The Pet Healthcare Product research report provides a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is reliable, comprehensive and the result of extensive research both primary

Related Stocks: MRK , BX , TSLA , GE , COP , LMT , GBCI , CBRE , GM , MRO , SCHC , AMPL , MO , CMP , VTR , ADBE , SPTS , UOCT ,

Related Stocks: CSCO , RRX , MRK , ADI , FIS , PFE , TASK , GLOB , ON , LNG , CROX , SIVB , DRI , COF , MU , EHC , WEC , COMM ,

Specialty Pharmaceutical Market 2022 Covid 19 Impact on Top countries data Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast New York, NY -- ( SBWIRE ) -- 02/09/2022 -- Specialty Pharmaceutical Market 2022-2028 A New Market Study, Titled "Specialty Pharmaceutical Market Upcoming Trends, Growth Drivers and Challenges" has been featured on fusionmarketresearch. Description This global study of the Specialty Pharmaceutical Market offers an overview of the existing market trends, drivers, restrictions, and metrics and also offers a viewpoint for important segments. The report also tracks product and services demand growth forecasts for the market. There is also to the study approach a detailed segmental review. A regional study of the global Specialty Pharmaceutical industry is also carried out in North America, Latin America, Asia-Pacific, Europe, and the Near East & Africa. The report mentions growth parameters in the regional markets along with major players dominating the regional growth.

Merck (MRK) and Ridgeback Biotherapeutics said ~3.1M courses of oral antiviral COVID-19 drug molnupiravir have been provided to the U.S

Merck & Co. and partner privately held Ridgeback Biotherapeutics said Tuesday they have completed manufacturing of 10 million doses of their COVID antiviral molnupiravir and are on track to make at least 20 million courses in 2022. The pair have supplied 3.1 million course to the U.S. government for use in the U.S., they said in a joint statement. "As we start 2022, more than 2,000 COVID-19 deaths are being reported in the U.S. daily, which underscores the need for medicines including molnupiravir that can be taken at home," Merck CEO Robert Davis said in the statement. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Callable Multi Barrier Reverse Convertible auf BioNTech, Johnson & Johnson, Merck, Moderna, Pfizer / Idorsia, Lonza, Novartis, Roche, Zur Rose Group AG

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish. Merck & Co., Inc. (NASDAQ: MRK ) issued mixed 2022 guidance and Swiss pharma giant Roche Holding AG (OTC: RHHBY ) warned of slowing growth in 2022. Biogen, Inc. (NASDAQ: BIIB ) shares moved to the downside as they reacted to weak guidance and not-so-promising commentary about sales of the company''s Alzheimer''s drug Aduhelm. On the regulatory front, the Food and Drug Administration approved Viatris Inc.''s (NASDAQ: VTRS ) generic version of AbbVie, Inc.''s (NYSE: ABBV ) dry eye disease drug Restasis. Sanofi (NASDAQ: SNY ) received the nod for its medication Enjaymo, targeting a rare blood disorder known as cold agglutinin disease. LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) shares shed over 50% during the week after the FDA imposed a clinical hold on a Phase 1/2 study of its AAV-delivered genomic editing therapy LB-001 to treat a rate metabolic disorder in children.

Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. Merck & Co Inc (NYSE: MRK ) shares pulled back despite the company reporting this week above-consensus results, with the negative reaction reflecting investors concerns over the sustainability of its oral COVID-19 pill revenues. Roche Holding AG (OTC: RHHBY ) also pulled back as the Swiss pharma giant flagged slowing COVID testing revenues. What Happened: Against this backdrop, money manager Cathie Wood''s Ark Invest sold a trio of biopharma stocks on Friday, according to daily trade information released by the fund. The ARK Genomic Revolution ETF (BATS: Full story available on Benzinga.com

MRK earnings call for the period ending December 31, 2021.

Merck & Co., Inc. (NYSE: MRK) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations Robert M. Davis — Chief Executive Officer and President Caroline… […] The post Merck & Co., Inc. (MRK) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker''s COVID-19 treatment debuted with nearly $1 billion in sales. Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday. Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion. Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street''s per-share projections of $1.53, according to a survey by the data firm FactSet. Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts. The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue. Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue. Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in ear